Taxanes Vinca alkaloids Antimetabolites

75 terms by benmarler123 

Create a new folder

Advertisement Upgrade to remove ads

Chemotherapy

Taxane Agents

Cabazitaxel (Jevtana)
 Docetaxel (Taxotere)
 Paclitaxel (Taxol)
 Albumin-bound paclitaxel (Abraxane)
 Ixabepilone (Ixempra)

Vinca Alkaloids

Vinblastine
 Vinorelbine
 Vincristine

Anti-mitotic Agent

Eribulin (Halaven)

Microtubules fjunction

Principle components of the mitotic spindle apparatus
 Separate the duplicate set of chromosomes during mitosis
 Function to maintain the scaffolding and shape of the cell
 Assembled by linear stacking of alternating units of alpha and beta tubulin

Tubulin polymerization function

Nucleation - elongation mechanism that allows a microtubule to shorten and elongate according the the cell cycle
Microtubules are in a constant state of motion (assembling and
disassembling)

Microtubule Dynamics

Treadmilling: net growth at one end of the microtubule (plus
end) and net shortening at the opposite end (minus end)
 Dynamic instability: microtubule ends switch spontaneously
between states of slow sustained growth and rapid shortening

Microtubule have 2 ends

Plus end: More rapid and polymerization
Minus end: Faster release Of subunits (depolymerization)

Taxane Agents Mechanism of Action

M phase specific,
Binds β-tubulin subunit of the microtubule and prevents disassembly (depolymerization) of the tubulin
 Results in formation of stable, nonfunctional microtubules
 Cell is unable to complete cell division and undergoes
apoptosis

Paclitaxel (Taxol) Uses

Majority of solid tumors
 Breast, Lung, Ovarian,
Testicular, Head and Neck,
among others

Paclitaxel (Taxol) Toxicities

Neutropenia (DLT)
 Nausea / Vomiting
 Peripheral neuropathy
 Alopecia
 Arthralgia / Myalgia
 Anaphylactic
hypersensitivity (due to
Cremaphor)
 Flushing / Rash
 Cardiac arrhythmias

Paclitaxel (Taxol) Dose Adjustment

Hepatic dysfunction
 Hepatic metabolism
through CYP 2C8

Paclitaxel (Taxol) Special Compounding

Drug is diluted in 50/50
Cremaphor (castor oil) and
alcohol
 DO NOT MIX in PVC
 Plasticizer DHEP leaches
into solution = Toxic

Paclitaxel (Taxol) Premedications
(30 minutes prior)

Histamine-2 receptor
antagonist
 Famotidine 20mg IV
 Diphenhydramine 25 mg
IV
 3 doses of dexamethasone:
12 - 20 mg PO at 12, 6 and
1 hour prior to paclitaxel
 Antiemetics

Albumin-Bound Paclitaxel (Abraxane)

Indicated only in metastatic breast cancer following
progression of an anthracycline-based therapy
 Similar toxicities to paclitaxel
 LOWER risk of hypersensitivity reaction
 HIGHER rate of peripheral neuropathy and neutropenia
 Dosing adjustments for hepatic dysfunction

Docetaxel (Taxotere) Uses

Solid tumors primarily
 Prostate, Breast, Lung,
Ovarian, Bladder, Head
and Neck

Docetaxel (Taxotere) Toxicities

Neutropenia (DLT)
 Peripheral neuropathy
 Alopecia
 Fluid retention
 Anaphylactic
hypersensitivity (due
toTween 80)
 Arthralgia / Myalgia
 Nausea / Vomiting
 Flushing / Rash

Docetaxel (Taxotere) Dose Adjustment

Hepatic dysfunction
 Hepatic metabolism through
CYP 3A4/5*

Docetaxel (Taxotere) Special Compounding

Drug is diluted in Polysorbate
80 and alcohol
 DO NOT MIX in PVC
 Plasticizer DHEP leaches into
solution = Toxic

Docetaxel (Taxotere) Premedications (30 minutes prior)

Diphenhydramine 25 mg
 Dexamethasone 8mg PO BID
beginning day before
docetaxel and continuing for
3 days (reduces edema)
 Antiemetics

Ixabepilone (Ixempra) approved for

Only approved for use in breast cancer after failure of
anthracyclines, taxanes and capecitabine

Ixabepilone (Ixempra) Toxicities

Peripheral neuropathy (DLT)
 Neutropenia
 Myocardial ischemia
 Myalgia
 Fatigue
 Nausea
 Anaphylactic hypersensitivity
(contains Cremaphor*)
 Premedicate like paclitaxel

Ixabepilone (Ixempra) dosing limitations

Dose reduce in hepatic dysfunction

Ixabepilone (Ixempra) Epithilone Drug Class MOA:

Binds to beta-tubulin (occupies different binding site than taxanes)
 5 - 25x more potent than
paclitaxel

Eribulin (Halaven) MOA

non-taxane microtubule inhibitor, halichondrin B analog which inhibits growth phase of microtubules by inhibiting formation of
mitotic spindle

Eribulin (Halaven) Uses

Metastatic breast cancer

Eribulin (Halaven) Toxicities

Myelosuppression
 Neutropenia
 Anemia
 QTc prolongation
 Peripheral neuropathy
 Alopecia

Cabazitaxel (Jevtana) Uses

Hormone refractory metastatic prostate cancer

Cabazitaxel (Jevtana) Toxicities

Neutropenia
 Neuropathy
 Hypersensitivity reaction
(contains polysorbate 80)
 Premediate like paclitaxel
 Nausea / vomiting /
diarrhea
 Arthralgia
 Alopecia

Vinca Alkaloids MOA

Inhibit tubulin polymerization  Block ability to form a
mitotic spindle
 Cell is unable to complete cell division and undergoes
apoptosis

Taxanes Vinca alkaloids MOA diagram

Vincristine (Oncovin) Uses

Leukemia, Lymphoma

Vincristine (Oncovin) Toxicities

Peripheral neuropathy
(DLT)
 Paralytic ileus
 Prophylactic stool
softeners
 2 tabs QHS - titrate to regulate bowel movements
 SIADH
 Minimal nausea
MAX dose = 2 mg  Vesicant

Vincristine (Oncovin) dose adjustments

 Hepatic
 Requires dosing
adjustment for hepatic
insufficiency

Vinblastine (Velban) Uses

Lymphoma, melanoma

Vinblastine (Velban) Toxicities

Neutropenia (DLT)
 Thrombocytopenia
 Alopecia
 Mild peripheral neuropathy
 SIADH
 Minimal nausea
 Vesicant

Vinblastine (Velban) dose adjustments

Requires dosing adjustment for hepatic insufficiency

Compounding Vinca Alklaloids

FATAL if given by intraTHECAL route
 Slow, painful death from myeloencephalopathy
 Ascending motor and sensory neuropathy
 World Health Organization recommends compounding these
drugs in a piggyback
 NO Syringes = NO confusion for intrathecal administration

"S" Phase Agents Antimetabolites

Methotrexate
Pemetrexed
Fluouracil / Capecitabine
Mercaptopurine
Thioguanine
Fludarabine
Pentostatin
Gemcitabine
Cytarabine
Azacytidine
Decitabine

Antifolate Drugs

Methotrexate and Pemetrexed

S Phase Specific Activity antifolate Deficiency

impairs thymidylate and purine synthesis (DNA synthesis)
 Megaloblastic anemia

Methotrexate (Trexall) Uses

Leukemia, Lymphoma
 Various solid tumors
(sarcoma, breast, head and
neck, choriocarcinoma)
 Non-oncology
 Psoriasis, rheumatoid arthritis,
Crohn's disease, graft versus
host therapy, abortifacient

Methotrexate (Trexall) MOA

Inhibits the enzyme dihydrofolate reductase
 DHFR replenishing cell's tetrahydrofolate supply
 Increasing levels of dihydrofolate inhibits activity of thymidylate synthase
 Blockade of DHFR = inhibition of thymidylate and purine
synthesis

Methotrexate (Trexall) Special Notes

Wide variability in dosing!
 2.5 mg once a week - 20 grams once a month
 PO, IV, can give intrathecally
 Eliminated in urine -adjust dose for renal dysfunction
 High protein binding
 3rd space fluid collection (pleural effusions, ascites)

Methotrexate (Trexall) Toxicities

Mucositis
 Myelosuppression (neutropenia, thrombocytopenia)
 Renal toxicity
 Pneumonitis
 Alopecia
 Infertility

High-Dose Methotrexate can

High - dose methotrexate, Requires urine alkalinization (pH >
7.5), Requires high volume hydration (250 ml/m2/hr) for renal
protection, Requires leucovorin rescue which will rescue both healthy and malignant cells

High-Dose Methotrexate Leucovorin rescue

Initiated > 24 hours after the dose of methotrexate
 20 mg IV/PO Q6H
 Increase dose based on algorithm
 Treat with leucovorin until methotrexate level < 1 x 10 -7 molar

Mucositis Tx

Supportive Care
 IV/PO pain medication
 Saliva substitute
 Soft tooth brush and baking soda water rinse
 Cryotherapy
 "Magic Mouth Wash"
 Hydrocortisone 110 mg IV, Diphenhydramine elixer 120 mL, Nystatin
suspension 120 mL (may substitute Maalox, tetracycline, sucralfate)
 5 - 10 mL PO Q4H prn pain
 +/- viscous lidocaine 2% (beware of cardiac adverse effects)

Pemetrexed (Alimta) Uses

Non-small cell lung cancer, drug of choice for mesothelioma

Pemetrexed (Alimta) MOA

Multi-targeted
 Inhibits thymidylate synthase
 Weakly inhibits DHFR
 Inhbitis GARFT (glycinamide ribonucleotide formyltransferase) - enzyme necessary for purine synthesis

Pemetrexed (Alimta) Toxicities and Supportive Care

Myelosuppression
 At least 7 days prior to 1st dose:
 Cyanocobalamin 1000 mcg IM then every 9 weeks
 Folic acid 1 mg PO daily
 Pruritic rash (40%)
 Dexamethasone 4 mg BID day -1, day 0 and day +1 t
 Prevention of rash

Antifolate mechanism of action

Fluouracil (5-FU, Adrucil) is

Fluorinated analog of naturally occurring pyrimidine of uracil that is S-phase specific

Fluouracil (5-FU, Adrucil) MOA

Monophosphate form of 5-FU (F-dUMP) inhibits thymidylate
synthase
 Competes with natural substrate, dUMP for
thymidylate synthase binding
 dUMP required to make thymidine (building block of DNA)
 Triphosphate form of 5-FU (FUTP) incorporates into RNA as
a false base pair

5-FU drug Interactions

Leucovorin
 Addition of folates during 5-FU infusion increases the stability of the 5-FU monophosphate - thymidine sythase bond
 Results in increased
cytotoxic activity
Warfarin
 Increased PT/INR
Phenytoin
 Increased phenytoin levels
Radiation
 Radio-sensitizer

Fluoruracil Uses

Breast, Colorectal, Gastric, Esophageal, Head and Neck, Pancreatic, Cervical Cancer

Fluoruracil Toxicity

Myelosuppression
 Mucositis
 Diarrhea
 Palmar-Plantar erythema (Hand-Foot Syndrome)
 Photosensitivity
 Mild Nausea
 Neurotoxicity

Capecitabine (Xeloda) FDA indicated

Colorectal Cancer (CRC)
 Single agent for adjuvant therapy after complete tumor
resection*
 Single agent, first line therapy in metastatic CRC

Metastatic Breast Cancer
 Single agent
 In combination with docetaxel or lapatinib

Antipyrimidine Antimetabolites Cytidine Analogues

Cytarabine
Gemcitabine
Azacytidine
Decitabine

Cytarabine (Ara-C) Uses

Leukemia and Lymphoma
 No activity in solid tumors

Cytarabine (Ara-C) Elimination

Enzyme cytidine deaminase
deactivates Ara-C
 Enzyme present in low levels in
the CNS
 Effective for intrathecal
administration
 Dose adjust for renal dysfunction
(increased neurotoxicity)

Cytarabine (Ara-C) MOA

Analog of deoxycytidine
 Incorporates into DNA
 Terminates chain elongation
 Inhibits DNA polymerase
 Cytarabine is phosphorylated to an active triphosphate form (aca-CTP) within tumor cells

Cytarabine (Ara-C) Adverse Effects

Myelosuppression
 Conjunctivitis
 Nausea / Vomiting
 Skin rash (palmar-plantar)
 Cerebellar toxicity
 LFT elevation (transient)
 Diarrhea

Gemcitabine (Gemzar) Uses

Bladder, Pancreatic, Lung, Breast,
Ovarian Cancer
 Radiation sensitizer

Gemcitabine (Gemzar) Toxicities

Edema
 Acute respiratory distress syndrome
 Rash
 Nausea / Vomiting
 Thrombocytopenia - DLT
 Flu-like symptoms
 Transient elevation in LFTs

Gemcitabine (Gemzar) MOA

Analog of deoxycytidine
 Incorporates into DNA
 Terminates chain elongation
 Competes with the natural substrate, dCTP (deoxycytidine triphosphate), for DNA incorporation
 Inhibits DNA polymerase
 Inhibits DNA synthesis
 Inhibiting an enzyme responsible for the production of deoxynucleotides, ribonucleotide reductase

Azacytidine (Vidaza) & Decitabine (Dacogen) Uses and MOA

Myelodysplastic syndrome
Acute myeloid leukemia
 Limited activity

Hypomethylating agents
Incorporated into DNA and RNA

Azacytidine (Vidaza) & Decitabine (Dacogen) Elimination

Enzyme cytidine deaminase
deactivates Ara-C

Purine Antimetabolites Guanine Analogs

6-mercaptopurine (6-MP,Purinthol)
6-Thioguanine (6-TG)
Azothioprine (Imuran)

Purine Antimetabolites Adenosine Analogs

Pentostatin
Cladribine (2-cda, Leustatin)
Fludarabine (Fludara)

Guanine Analogs (6-MP, 6-TG) MOA and Uses

Converted to ribonucleotides that are incorporated into DNA
 Inhibit purine synthesis

Uses: Leukemia

Guanine Analogs (6-MP, 6-TG)

Allopurinol increases 6-MP toxicity
 6-MP is metabolized by xanthine oxidase
 Allopurinol is a xanthine oxidase inhibitor

Adenosine Analogs Fludarabine Cladribine & Pentostatin Uses

lymphoma

Adenosine Analogs Fludarabine MOA

Inhibits DNA polymerase and ribonucleotide reductase,
incorporated into DNA

Cladribine & Pentostatin Adenosine Analogs MOA

Inhibits ribonucleotide reductase
 Unlike fludarabine, these drugs are not deactivated by adenosine deaminase (cladribine inhibits AD)

Adenosine Analogs Fludarabine Cladribine & Pentostatin cause

DLT - myelosuppression (T cell depression)
 Risk of opportunistic infections of PCP, HSV
 *Recommend anti-infective prophylaxis*

Please allow access to your computer’s microphone to use Voice Recording.

Having trouble? Click here for help.

We can’t access your microphone!

Click the icon above to update your browser permissions above and try again

Example:

Reload the page to try again!

Reload

Press Cmd-0 to reset your zoom

Press Ctrl-0 to reset your zoom

It looks like your browser might be zoomed in or out. Your browser needs to be zoomed to a normal size to record audio.

Please upgrade Flash or install Chrome
to use Voice Recording.

For more help, see our troubleshooting page.

Your microphone is muted

For help fixing this issue, see this FAQ.

Star this term

You can study starred terms together

NEW! Voice Recording

Create Set